The user is seeking affordable alternatives for oral finasteride and minoxidil in the UK due to high costs. They have been using these treatments from Sons with positive results.
Topical diazoxide may be a promising hair regrowth treatment, especially for those who don't respond to minoxidil, as it activates potassium channels without needing sulfation. It appears safe for topical use, avoiding systemic effects seen in oral use.
Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.
User quit minoxidil and finasteride, starting stemoxydine, dermastamp, and dermapen for hair loss. Seeks advice on alternatives, avoiding androgen disruptors and vasodilators/vasoconstrictors.
The user is seeking advice on safe hair loss treatments for a household with pets, avoiding minoxidil due to its danger to cats. They are considering alternatives like dutasteride and looking for affordable options.
A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
OP used minoxidil for 15 months and pyrilutamide for 46 days, achieving desired results without side effects. Users discussed alternatives like dutasteride and finasteride, with concerns about side effects like erectile dysfunction.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.